Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
Status:
Terminated
Trial end date:
2017-01-28
Target enrollment:
Participant gender:
Summary
The primary aim of this study is to evaluate the effect of Exendin (9-39) on glucose
requirements to maintain euglycemia in pediatric patients with congenital hyperinsulinism
(CHI) who have failed medical therapy. The secondary aims are to determine the therapeutic
plasma levels, plasma half-life and pharmacokinetics of Exendin (9-39) during a 9-hour
intravenous infusion.